Log in to save to my catalogue

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5996391

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

CD19-specific CAR T cells were produced centrally for a global study in young people with relapsed B-cell ALL. The overall remission rate was 81%, and patients with a response were negative for minimal residual disease. High-grade toxic effects were frequent but treatable.

Alternative Titles

Full title

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5996391

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5996391

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1709866

How to access this item